Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Impact · against what's priced in

Spero Therapeutics (SPRO) has established a clear binary catalyst with a PDUFA date of June 18, 2026, and significantly reduced near-term bankruptcy risk via a cash runway extending into 2028. GSK remains a secondary beneficiary through its license to the drug, though the impact on its valuation is marginal.

SPRO+0.60

No priced-in read yet